Given the reduction in expression of phospho AKT and NF-kB, along with the reduced expression of VEGF-A in DU145 and 22Rv1 prostate cancer cells treated with VK2, we next sought to determine whether treatment with VK2 reduces angiogenesis in vivo. This evidence concerns the gene AKT1 and prostate carcinoma.